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Human T-lymphotropic virus type 1 (HTLV-1) p12I localizes to the endoplasmic reticulum and Golgi causing sustained release of calcium, T
cell activation, and enhanced expression of several calcium-regulated genes. In recent microarray studies, p300 mRNA was increased in T cells
expressing p12I. The co-activator p300 is a key regulator of cellular and viral transcription; however, factors that influence its transcriptional
regulation are less well studied. We hypothesized that the transcription of p300 is calcium dependent and that sustained low magnitude increases in
intracellular calcium may enhance the transcription of p300. Herein, we report enhanced expression of p300 in T cells by p12I in a calcium-
dependent, but calcineurin-independent manner. Sustained low magnitude calcium release induced by ionomycin in T cells was sufficient to
increased mRNA and protein levels of p300 resulting in enhanced transcription from a p300-dependent promoter. Promoter analysis of the p300
gene was used to predict calcium-responsive transcription factor binding sites. Using mutant forms of p12I, we demonstrate that ER localization of
the viral protein is required to increase p300. In addition, p12I reversed the repression of HTLV-1 LTR-driven transcription by HTLV-1 p30II, a
p300-binding protein. HTLV-1 p12I-mediated enhancement of p300 expression represents a novel mechanism of regulation of cellular gene
expression by viral proteins. By targeting a ubiquitous second messenger such as calcium, HTLV-1 p12I may regulate the expression of the cellular
transcriptional co-activator p300 to modulate viral gene expression and promote lymphocyte survival.
© 2006 Elsevier Inc. All rights reserved.Keywords: Calcium; p300; Retrovirus; HTLV-1; Accessory protein; TranscriptionIntroduction
p300 is an important regulator of the transcription apparatus
in response to a variety of cell signaling pathways that
determines cell proliferation, differentiation, and apoptosis. As
a transcriptional co-activator, p300 interacts with various⁎ Corresponding author. Department of Veterinary Biosciences, The Ohio
State University, 1925 Coffey Road, Columbus, OH 43210, USA. Fax: +1 614
292 6473.
E-mail address: lairmore.1@osu.edu (M.D. Lairmore).
1 Current address: Merck Research Laboratories, Merck and Co., Inc.,
Sumneytown Pike, PO Box 4, West Point, PA 19486-0004, USA.
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.06.005cellular and viral promoter elements by bridging together
transcription factors or modifying, through histone acetyltrans-
ferase activity, the structure of nucleosomal histones (Chan and
La Thangue, 2001). A large number of sequence-specific,
DNA-binding factors form complexes with p300, including
nuclear steroid receptors, c-Jun, Fos, p53, Sap1, Stat1 and Stat2,
MyoD, Ets-1, NFκB, HIF1, GATA 1, cMyb, and Smad proteins
(Blobel, 2002; Iyer et al., 2004). In addition, p300 interacts with
TBP, TFIIB, TFIID, RNA helicase A, CREB, MAP kinase
p90rsk, and RNA polymerase II (reviewed in Janknecht, 2002;
Goodman and Smolik, 2000; Vo and Goodman, 2001). Several
viral proteins also interact with p300, including HTLV-1 p30II
and Tax, adenovirus E1A, HIV-1 Vpr and Tat, Kaposi's
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regulatory factor protein (vIRF), simian virus 40 large T
antigen, HPV E6 and E7, small delta antigen of hepatitis delta
virus, Epstein–Barr virus (EBV) nuclear antigen 3C (EBNA3C)
and EBNA2, and herpes simplex virion protein-16 (VP16)
(Ludlow and Skuse, 1995; Marzio and Giacca, 1999; Goodman
and Smolik, 2000; Ali and Decaprio, 2001; Kashanchi and
Brady, 2005; Zhang et al., 2001).
p300 mediates the activities of various transcription factors;
however, its availability in the cell is limited (Petrij et al., 1995).
A variety of cellular proteins are known to compete with each
other for binding to p300 (Colgin and Nyborg, 1998). This
environment of competition between transcription factors for
co-activator binding provides an additional layer of tightly
regulated gene expression. Competition between viral and
cellular proteins for binding p300 has been reported for HIV,
adenovirus, and SV40 (Hottiger et al., 1998; Yang et al., 1996).
The activities of p300 are regulated through competitive
protein–protein interactions or post-translational modifications
such as phosphorylation and acetylation (Chan and La Thangue,
2001; Giordano and Avantaggiati, 1999). However, the
transcriptional regulation of p300 remains to be elucidated.
A doubly spliced mRNAwithin the most distal 3′ end of the
HTLV-1 genome encodes both positive regulators of viral gene
expression, the Rex and Tax proteins from ORFs III and IV,
respectively (reviewed in Younis and Green, 2005; Grassmann
et al., 2005; Kashanchi and Brady, 2005). In HTLV-1, both the
singly and doubly spliced ORF I mRNAs encode a protein of
12 kDa (p12I) (Ciminale et al., 1992; Koralnik et al., 1993). A
unique doubly spliced mRNA from ORF II encodes p30II
(Ciminale et al., 1992), whereas a singly spliced mRNAwithin
the same ORF II encodes p13II (Berneman et al., 1992; Koralnik
et al., 1993). Nucleotide sequence alleles of p12I including
those that would result in specific residue changes associated
with protein stability (lysine versus arginine at position aa 88) or
truncation mutants have been reported in a minority (<7%) of
HTLV-1-infected subjects with HAM/TSP, ATL, and asympto-
matic patients (Martins et al., 2002; Furukawa et al., 2004;
Iniguez et al., 2006). The influence of these HTLV-1 variants in
viral transmission or disease outcomes is unclear. We have
reported that ablation of the acceptor splice site for the singly
and doubly spliced ORF I mRNA is associated with a reduction
of viral infectivity in vivo (Collins et al., 1998) that can be
modeled when resting T cells are used as targets in vitro
(Albrecht et al., 2000).
p12I localizes to the endoplasmic reticulum and Golgi,
where it associates with two resident calcium-binding proteins,
calreticulin and calnexin (Ding et al., 2001) causing sustained
release of calcium (Ding et al., 2002), leading to activation of
nuclear factor of activated T cell (NFAT)-mediated transcription
(Albrecht et al., 2002). p12I also binds the calcium/calmodulin-
dependent serine/threonine phosphatase, calcineurin (Kim et al.,
2003). We have recently reported that p12I expression in Jurkat
T cells alters the expression of several calcium-regulated genes
(Nair et al., 2005). A surprising finding in this report was the
observation that p300 mRNA was increased in Jurkat and
primary human T cells during p12I expression (Nair et al.,2005). Based on this, we hypothesized that the transcription of
p300 is calcium dependent and that sustained low magnitude
increase in intracellular calcium concentration would enhance
the transcription of p300.
Herein, we report that HTLV-1 p12I increases the expres-
sion of p300 mRNA and protein in T cells. The enhanced p300
expression was calcium dependent, but calcineurin indepen-
dent. We demonstrate that ionomycin, a well-characterized
calcium ionophore that triggers calcium release in Jurkat T
cells, causes increased mRNA and protein levels of p300
sufficient to enhanced transcription from p300-dependent
reporter genes. Furthermore, this p300-dependent transcrip-
tional activity could be blocked by BAPTA-AM, a known
calcium chelator, whereas cyclosporine A, a calcineurin
inhibitor, did not have any effect on the p300-dependent
transcriptional activity. In addition, using an ER-localization-
deficient mutant of HTLV-1 p12I, we demonstrate that ER
localization of p12I is required for its ability to increase p300.
In a dose-dependent manner, the expression of p12I reversed
HTLV-1 p30II-mediated repression of HTLV-1 LTR-driven
transcription. As p30II is a p300-binding protein, these data
illustrate that HTLV-1 accessory proteins may act together to
balance viral expression. Collectively, HTLV-1 p12I appears to
regulate the expression of the key cellular transcriptional co-
activator p300 through the ubiquitous second messenger
calcium to modulate viral gene expression and promote long-
term T lymphocyte survival.
Results
HTLV-1 p12I enhances expression of p300
We have reported that the expression of p12I in Jurkat T cells
and primary CD4 T lymphocytes is associated with enhanced
expression of p300 mRNA and increased p300-mediated
transcription in Jurkat T cells (Nair et al., 2005). To test
whether expressing p12I in T cells results in increased p300
itself, we performed western immunoblot assays from Jurkat T
cells spin infected with recombinant lentiviral vectors. Our data
indicated that Jurkat T cells expressing p12I had ∼2.1-fold
higher protein levels of p300 compared to mock vector-infected
control Jurkat T cells (Figs. 1A and B).
Sustained low magnitude increase in intracellular calcium
enhances the levels of p300 by increasing its transcription
Previous reports from our laboratory demonstrated that
HTLV-1 p12I increases cytosolic calcium by enhancing release
from ER stores (Ding et al., 2002). Increased intracellular
calcium levels have been extensively studied using calcium
ionophores, such as ionomycin (Liu and Hermann, 1978).
Ionomycin is routinely used for investigating calcium-mediated
T cell activation and proliferation. At high concentrations (0.5–
2.0 μM), typically used to study proliferative responses of cells
to calcium, ionomycin mediates passive calcium influx by
directly inserting into the plasma membrane (Donnadieu et al.,
1995). However, at 10- to 100-fold lower concentrations (50–
Fig. 2. Sustained low magnitude increase in intracellular calcium concentration
enhances transcription of p300. (A) Jurkat T cells (1 × 106 per ml) were
stimulated with varying concentrations of ionomycin for 36 h. Total cellular
RNAwas extracted and semi-quantitative RT-PCR was performed to identify the
mRNA levels of p300. There was a dose-dependent increase in p300 expression
in Jurkat T cells stimulated with low concentrations of ionomycin (25, 50, and
100 nM). (B) Densitometric analysis was performed using alpha imager
software and normalized to GAPDH. Dose-dependent increases (up to 2.4-fold)
in p300 mRNA were observed in Jurkat T cells stimulated with 100 nM
ionomycin. Statistical analysis was performed using Student's t test, P < 0.05.
Fig. 3. Enhanced mRNA levels of p300 correlates with increased protein levels
of p300. (A) Jurkat T cells (1 × 106 per ml) were stimulated with varying
concentrations of ionomycin for 60 h. Total protein was extracted and western
immunoblot analysis for the detection of p300 protein. There was a dose-
dependent increase in p300 expression in Jurkat T cells stimulated with low
concentrations of ionomycin (25, 50, and 100 nM). (B) Densitometric analysis
of radiograph was performed using Gel pro analyzer software and normalized to
GAPDH. Dose-dependent increases (up to 2.5-fold) of p300 were observed in
Jurkat T cells stimulated with 100 nM ionomycin. The protein levels were in
parallel with mRNA levels observed at similar concentrations of ionomycin.
Statistical analysis was performed using Student's t test, P < 0.05.
Fig. 1. HTLV-1 p12I enhances p300 protein levels in Jurkat T lymphocytes. (A)
Jurkat T lymphocytes (2 × 106) were spin infected with lentiviral vectors
expressing p12I at an MOI of 5. Total protein was extracted and western
immunoblot analysis for the detection of p300 was performed. Jurkat T cells
expressing p12I demonstrated increased protein levels of p300. (B) Densito-
metric analysis of radiograph was performed using Gel pro analyzer software
and normalized to GapDH. Jurkat T cells expressing p12I showed ∼2.1-fold
increased expression of p300. Statistical analysis was performed using Student's
t test, P < 0.05.
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increases cytosolic calcium by depletion of intracellular calcium
stores and capacitative calcium entry (Donnadieu et al., 1995;
Putney, 1990). Thus, stimulation of T cells with 50–100 nM of
ionomycin causes calcium influx similar to HTLV-1 p12I (Ding
et al., 2001).
To test if low magnitude increase in intracellular calcium
mediated through ionomycin enhances the expression of p300,
we performed semi-quantitative RT-PCR on total RNA
extracted from Jurkat T cells stimulated with ionomycin. The
cells were stimulated with 25, 50, 100, 500 nM, and 1 μM of
ionomycin for 36 h before RNA extraction. Our data indicated
that p300 expression was increased in a dose-dependent manner
up to 100 nM of ionomycin in Jurkat T cells, 1.5, 1.8, and 2.4,
respectively (Figs. 2A and B). p300 mRNA were not
significantly altered at higher concentrations of ionomycin
(500 nM and 1 μM) due to reduced cell viability at these higher
concentrations, a known property of high dose ionomycin
treatments.
To investigate if increased levels of p300 mRNA correlated
with a corresponding increase in protein levels of p300, we
performed western immunoblot assays using Jurkat T cells
stimulated with these same concentrations of ionomycin. Our
data indicated a dose-dependent increase in p300 in Jurkat T
cells stimulated with these lower concentrations of ionomycin.
The fold increase in p300 protein levels in cells treated with 25,
50, and 100 nM of ionomycin were 1.2, 1.6, and 2.4,
respectively (Figs. 3A and B). Densitometry values were
normalized to constitutively expressed GAPDH in both RT-
PCR and western immunoblot assays.
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To investigate whether the increased levels of p300 observed
during low dose ionomycin treatment resulted in enhanced
transcription from p300-dependent promoters, we tested the
effect of low dose ionomycin in a VP16-mediated transactiva-
tion assay (Nair et al., 2005). Our data indicated that low dose
ionomycin elicited a dose-dependent increase in VP16-
mediated transactivation (Fig. 4A). Approximately 3.3- to 4.4-
fold higher luciferase values were observed at 50 and 100 nM
concentrations of ionomycin (Fig. 4A). To further confirm that
this increased luciferase activity was specific to increased levelsFig. 4. Ionomycin-mediated increase in p300 influences transcription. (A)
2 × 106 Jurkat T cells were transfected with 5xGT-Luc and pM-VP16. The
transfected cells were maintained in cRPMI medium containing increasing
concentrations of ionomycin. The luciferase activity was tested 60 h post-
transfection. A dose-dependent increase in VP16-mediated p300-dependent
luciferase activity was observed with increasing concentrations of ionomycin.
(B) The increase in VP16-mediated luciferase activity was confirmed to be p300
dependent by transfecting wild-type and mutants of adenoviral E1A protein.
Two million Jurkat T cells were transfected with 5xGT-Luc, pM-VP16, and
increasing concentrations of wild-type or mutants of adenoviral E1A protein.
The transfected cells were incubated in cRPMI medium supplemented with
100 nM ionomycin.ΔCR1 mutant of E1A is incapable of binding p300 whereas
ΔCR2 mutant is capable of binding p300 but not retinoblastoma protein. VP16-
mediated p300-dependent luciferase activity was inhibited in a dose-dependent
fashion in the presence of wild-type as well as ΔCR2 mutant of E1A. No effect
on luciferase activity occurred in the presence of ΔCR1 mutant of E1A.
Fig. 5. Enhanced expression of p300 is calcium dependent, but calcineurin
independent. (A) Jurkat T cells (2 × 106) were transfected with 5xGT-Luc and
pM-VP16 and incubated in cRPMI medium supplemented with 100 nM
ionomycin. The cells were treated with increasing concentrations of BAPTA-
AM or CsA. A dose-dependent reduction in VP16-mediated p300-dependent
luciferase activity was noticed in the presence of BAPTA-AM whereas no
significant difference in luciferase activity was observed in the presence of CsA.
(B) Jurkat T cells (2 × 106) were transfected with 5xGT-Luc, pM-VP16, and
pME-p12I and incubated in cRPMI medium. The cells were treated with
increasing concentrations of BAPTA-AM or CsA. A dose-dependent reduction
in VP16-mediated p300-dependent luciferase activity was evident in the
presence of BAPTA-AM, whereas no significant difference in luciferase activity
was observed in the presence of CsA.of p300, we co-transfected and adenoviral E1A expressing
plasmid, which completely inhibits p300 transcription by
directly binding to the transcriptional co-adaptor. Plasmids
expressing wild-type E1A or mutants of E1A, including ΔCR1
that contains a mutation in the p300-binding region and ΔCR2
containing a mutation in the retinoblastoma-binding region
were transfected with the luciferase reporter plasmid and pM-
VP16. Wild-type E1A and the ΔCR2 mutant of E1A inhibited
the transactivation of VP16 in a dose-dependent manner (Fig.
4B). Our data indicated up to 82.3% reduction in luciferase
activity with wild-type E1A and approximately 70.0% reduc-
tion with the ΔCR2 mutant of E1A (Fig. 4B). The ΔCR1
mutant, which is unable to bind p300, did not have any effect on
luciferase activity, indicating the p300-dependent nature of
251A.M. Nair et al. / Virology 353 (2006) 247–257VP16-mediated transactivation (Fig. 4B). These findings
indicate that low magnitude increases in intracellular calcium
enhance p300 expression to functionally significant levels.
Enhanced expression of p300 is calcium dependent, but
calcineurin independent
We then confirmed that p12I enhancement of p300-
dependent VP16-driven transactivation was mediated by
calcium by transfecting our p12I expression plasmid into Jurkat
T cells in the presence of the calcium chelator BAPTA-AM (Fig.
5). In addition, we also stimulated Jurkat T cells with ionomycin
with increasing concentrations of BAPTA-AM. p300-depen-
dent VP16-mediated transactivation was inhibited in the
presence of BAPTA-AM in a dose-dependent manner in both
p12I-transfected and ionomycin-stimulated Jurkat T cells. We
observed a 55% reduction in luciferase activity with 10 μM
BAPTA-AM in Jurkat T cells expressing p12I and 64%
reduction in luciferase activity in Jurkat T cells stimulated
with 100 nM ionomycin, respectively (Figs. 5A and B). We then
blocked the calcium-dependent phosphatase calcineurin by
using cyclosporin A. Calcineurin is the key enzyme required for
NFAT translocation to the nucleus. Both p12I-expressing and
ionomycin-stimulated Jurkat T cells exhibited no significant
difference in luciferase activity with increasing concentrations
cyclosporin A up to 200 nm (Figs. 5A and B). BAPTA-AM
alone did not have any significant effect on luciferase
expression without the presence of calcium. These data were
consistent with our previous data and indicated that the
expression of p300 is dependent on calcium, but not calcineurin.
The mechanisms of transcriptional regulation of p300,
including transcription factors that cooperatively bind the
p300 promoter, have not been defined. To gain initial insightTable 1
Selected putative transcription factor sites in p300 promoter a
Transcription factor N
po
Ets—family member ELF-2 (NERF1a) 1
Human zinc finger protein ZNF35 1
b zip family, induced by ER damage binds in association with NF-Y 6
STAT6: signal transducer and activator of transcription 6 10
Ikaros 1, potential regulator of lymphocyte differentiation 11
HMGI (Y) high-mobility group protein I (Y) factor 11
PAX6 paired domain and homeodomain 17
Myc-associated zinc finger protein (MAZ) 18
Gut-enriched Krueppel-like factor 20
c-Rel 26
NF-kappaB 26
Zinc finger transcription factor ZBP-89 27
Erythroid Krueppel like factor (EKLF) 27
Myeloid zinc finger protein MZF1 32
Nuclear factor of activated T cells 36
Brn-2, POU-III protein class 39
a mRNA nucleotide sequence for p300 (NM_001429) obtained from NCBI Web-b
site of p300 mRNA, 403 nucleotide sequences were analyzed using commercially av
transcription factor binding sites in the promoter region in the p300 gene (chromosom
letters denote the core sequence used by MatInspector (Genomatix). Matrix simulatio
factor binding sites, based from a 1.00 core simulation score of known nucleotide sinto predicted transcription factor binding sites in the p300
promoter, we located the mRNA nucleotide sequence for p300
(NM_001429) using a Web-based resource (NCBI nucleotide
database). Then proceeding from transcriptional start site of the
p300 mRNA to the beginning of the mRNA message, we
analyzed 403 nucleotide sequences to predict transcription
factor binding sites in the p300 promoter. Nucleotide sequences
for consensus or putative binding sites for a number of
transcription factor family members are represented in the
promoter region of p300. These include transcription factors
that are known to respond to calcium signaling such as NF-κB
and NFAT (Im and Rao, 2004; Quintana et al., 2005) (Table 1).
Localization of p12I to ER is required for enhanced expression
of p300
Previous studies from our laboratory demonstrated that ER
localization of HTLV-1 p12I is critical for the release of calcium
its enhancement of NFAT-mediated transcription (Ding et al.,
2003). We therefore tested whether ER localization of p12I is
required for its ability to enhance the expression of p300. An N-
and C-terminal deletion mutant of p12I containing amino acids
15–47 localizes to the nucleus and the ER localization of this
mutant requires the addition of an ER targeting signal KKLL
(Ding et al., 2003). This mutant allowed us the opportunity to
test if ER localization of p12I is required to enhance p300-
dependent transactivation by transfecting Jurkat T cells with
equal amounts of either the empty vector, wild-type p12I, 15–
47 mutant of p12I, or the ER redirected 15-47-KKLL chimeric
mutant along with the luciferase reporter and Gal4-VP16
expression plasmids. A marked reduction in the luciferase
activity, up to 70%, was observed in Jurkat T cells expressing
the 15–47 mutant of p12I, suggesting that ER localization ofucleotide
sition
Matrix simulation
score
Sequence
0–26 0.910 cgaggaGGAAgaggttg
2–24 0.963 aggaggAAGAggt
7–81 0.945 ccgCCACggccggcc
7–125 0.963 gcgaaTTCCcgagaactcg
2–124 0.934 tctcGGGAattcg
3–125 0.953 gcgAATTcccgag
2–190 0.900 ggcttgggcCCAGgcccgg
8–200 0.910 gtgcGAGGggccg
3–217 0.924 agaaaaggtaAGGGc
4–278 0.914 aaaggaacTTCCccc
4–278 0.964 ggGGGAagttccttt
0–292 0.971 acttcccccaCCCCctcgggtgc
7–289 0.915 cccgaggGGGTgg
7–333 0.985 gcGGGGa
8–378 0.975 cgagGAAAacc
1–403 0.946 cggccattttTAATtcttt
ased resource (http://www.ncbi.nlm.nih.gov/). Preceding from the predicted start
ailable software (Genomatix: http://www.genomatix.de/) to analyze and predict
e 22, contig-NT_01150.09,Homo sapiens chromosome 22). Base pairs in capital
n scores with great than 0.90 were selected from 66 total predicted transcription
equence binding sites.
Fig. 7. HTLV-1 p12I partially inhibits the transcriptional repression of p30II on
HTLV-1 LTR. (A) Jurkat T cells (2 × 106) were transfected with pTRE-Luc,
pME-p30II and increasing concentrations of pME-p12I and then incubated in
cRPMI medium. A dose-dependent increase in luciferase activity was observed
with increasing concentrations of p12I. (B) To confirm that the increased
luciferase activity from pTRE-Luc was dependent on increased levels of p300,
we transfected adenoviral E1A protein with the above-described plasmids.
These data indicated a marked reduction in luciferase activity in the presence of
252 A.M. Nair et al. / Virology 353 (2006) 247–257p12I is critical for its ability to enhance the expression of p300
(Fig. 6). This tenet was further supported by the ability of the
ER-targeted 15-47-KKLL mutant of p12I to partially (80% of
the wild-type levels) restore the luciferase activity (Fig. 6).
HTLV-1 p12I inhibits the transcriptional repression of p30II on
HTLV-1 LTR
p300 plays a crucial role in the regulation of viral gene
transcription from HTLV-1 LTR in infected cells by forming
complexes with other transcriptional factors (Lemasson et al.,
2002). HTLV-1 Tax transactivates LTR-driven transcription of
HTLV-1 genes, in part, through its interaction with the p300
(Bex and Gaynor, 1998). In addition, studies from our
laboratory have demonstrated that an accessory protein of
HTLV-1, p30II, inhibits transcription of viral genes from the
HTLV-1 LTR (Zhang et al., 2001). This inhibition involves the
interaction of p30II with p300 and making it unavailable for
transcriptional co-activation at the viral LTR (Zhang et al.,
2001). By transiently transfecting increasing concentrations of
pCMV-p300 with constant amounts of pME-p30IIHA plasmid,
studies from our laboratory demonstrated that p300 expression
reverses the p30II-dependent repression of LTR-luciferase
reporter gene activity (Michael et al., submitted for publication).
Because p12I has the ability to increase the levels of p300,
we hypothesized that p12I expression would reverse the
inhibitory effect of p30II on HTLV-1 LTR-driven transcription.
To test our hypothesis, we transfected increasing amounts of our
pME-p12IHA plasmid concurrently with a constant amount of
pME-p30IIHA plasmid in the presence of an HTLV-1 LTR-
responsive reporter gene. Our data indicated that p12I
expression reverses the p30II-dependent repression of LTR-
luciferase reporter gene activity in a dose-dependent manner
(Fig. 7). We did not observe alterations in the cellular
localization of p30II in the presence of p12I (data not shown).
To test if the p12I block of p30II repression of LTR reporter geneFig. 6. Accumulation of p12I to ER is required for enhanced expression of p300.
Jurkat T cells (2 × 106) were transfected with 5xGT-Luc, pM-VP16, along with
either of the following plasmids—pME control vector, pME-p12I, pME-15-47,
or pME-15-47KKLL, and then incubated in cRPMI medium. pME-15-47,
which accumulates in the nucleus of transfected cells (Ding et al., 2002),
exhibits a marked reduction in the VP16-mediated p300-dependent luciferase
activity. The activity was partially restored by redirecting the protein to the ER.
E1A.activity was p300 dependent, we co-transfected an adenoviral
E1A expression plasmid along with pME-p12IHA and pME-
p30IIHA plasmids and demonstrated that the expression of E1A
blocked the effect of p12I on p30II-mediated LTR repression
(Fig. 7). These data further confirmed that HTLV-1 p12I inhibits
the transcriptional repression of p30II on the HTLV-1 LTR in a
p300-dependent manner and establishes that HTLV-1 accessory
proteins have the capacity to act cooperatively to modulate viral
gene expression.
Discussion
HTLV-1, a human deltaretrovirus associated with lympho-
proliferative disorders, encodes nonstructural or “accessory”
proteins that modulate viral and cellular gene expression by
interaction with p300 or through calcium-dependent mechan-
isms (Michael et al., 2004; Albrecht and Lairmore, 2002). One
such protein encoded in pX ORF I of HTLV-1 is p12I, which
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associates with two resident calcium-binding proteins, calre-
ticulin and calnexin (Ding et al., 2001), causing sustained
release of calcium (Ding et al., 2002) leading to activation of
nuclear factor of activated T cell (NFAT)-mediated transcription
(Albrecht et al., 2002). We have reported recently that p12I
expression in Jurkat T cells alters the expression of several
calcium-regulated genes (Nair et al., 2005). Unexpectedly, we
observed that p300 mRNAwas increased in T cells during p12I
expression (Nair et al., 2005). We therefore hypothesized that
the transcription of p300 is calcium dependent and that
sustained low magnitude increase in intracellular calcium
concentration would enhance the transcription of p300. Our
data presented herein is the first to demonstrate that p300, an
important co-activator of transcription, is responsive to
sustained low magnitude increases in intracellular calcium.
Because p300 is limited in cells, the expression of p300 in long-
lived lymphocytes, such as memory T cells, would be
particularly important for their survival. Interestingly, HTLV-1
has been demonstrated to target memory T cells (Yoshie et al.,
2002; Lal et al., 1992). We demonstrate that ER localization of
p12I is required for its ability to increase p300. In addition, our
data indicate that p12I reverses the repression of HTLV-1 LTR-
driven transcription by HTLV-1 p30II. HTLV-1 p12I-mediated
enhancement of p300 expression represents a novel mechanism
of regulation of cellular gene expression by viral proteins. By
increasing calcium-mediated signaling HTLV-1 p12I enhances
the expression of p300, which would modulate viral gene
expression and favor cell survival. Collectively, our data
provide new insight into HTLV-1-mediated gene expression
and calcium signaling as a mechanism of transcriptional
regulation of p300.
Calcium is a universal and highly versatile intracellular
messenger, which plays a critical role in many varied biological
processes such as cell proliferation, cell cycle, transcription,
signal transduction, and apoptosis (Lewis, 2001). Calcium
fluxes in mammalian cells are achieved by altering the
amplitude and spatial distribution of intracellular calcium
(Berridge et al., 1999, 2000; Bootman et al., 2001). Calcium
mobilization in lymphocytes is accomplished by binding of
inositol 1,4,5-trisphosphate (IP3) to its receptor in the ER
membrane and subsequent rapid but transient release of Ca2+
from ER stores (Berridge, 1993). Alternatively, sustained
extracellular Ca2+ influx across the plasma membrane, by
store-operated or capacitative Ca2+ entry, is activated by
depletion of intracellular Ca2+ stores and operated through
store-operated Ca2+ channels (SOC) or calcium release-
activated Ca2+ channels (CRAC) (Clapham, 1995; Parekh and
Penner, 1997; Putney, 1990).
Based on DNA microarray analysis, Feske et al. (2001)
demonstrated that Ca2+ signals modulate the expression of
various genes involved in transcription, including c-Myc, c-Jun,
CREM, NFAT4, FosB, E2F3, IRF-1, IRF-2, NF-IL3A, Fra-2,
FLI1, and SMBP2. Calcium-dependent activation of a wide
variety of transcription factors, such as NFAT, NFκB, Elk-1,
Nur77, AP-1, ATF-2, and CREB, occurs through calmodulin-
dependent protein kinases and phosphatases (Aramburu et al.,2000; Rao et al., 1997; Tokumitsu et al., 1995). Whereas a small
transient spike of Ca2+ increase by store depletion activates
signaling pathways and transcription factors such as NFκB and
JNK (Dolmetsch et al., 1997), capacitative calcium entry and a
sustained Ca2+ increase are necessary to activate other
transcription factors, such as NFAT (Dolmetsch et al., 1997,
1998; Li et al., 1998).
To date, p300 has not been identified as a calcium-responsive
gene. In addition, the transcriptional regulation of p300 and
detailed examination of transcription complexes operative in
regulating p300 have not been reported. We used the mRNA
nucleotide sequence to predict transcription factor binding sites
in the p300 promoter. Our analysis indicates that the p300
promoter contains binding sites for a number of transcription
factor family members known to respond to calcium signaling
such as NF-κB and NFAT (Im and Rao, 2004; Quintana et al.,
2005), suggesting that calcium signaling has a role in
replenishing limiting amounts of cellular p300.
Typically, the role of calcium in various signal transduction
pathways has been investigated using relatively high concen-
trations (0.5–2.0 μM) of calcium ionophores, such as
ionomycin, for short periods of time (6–18 h). This stimulation
condition simulates calcium-dependent T cell activation upon
antigen binding to the T cell receptor; however, such stimulation
protocols do not simulate the effect of prolonged stimulation
with calcium. Higher concentrations of ionomycin are cyto-
toxic, limiting the possibility of long-term stimulation. This
might explain why previous studies did not identify p300 as a
calcium-regulated gene. At low concentrations (50–100 nM),
ionomycin binds cellular endomembranes and increases
cytosolic calcium concentration by depletion of intracellular
calcium stores and capacitative calcium entry (Donnadieu et al.,
1995; Putney, 1990). Low concentrations of ionomycin there-
fore appear to simulate the effect of HTLV-1 p12I, which causes
sustained increases in intracellular calcium concentration (Ding
et al., 2002).
A number of viruses encode proteins that modulate cellular
Ca2+ homeostasis to regulate various aspects of viral pathogen-
esis (Ganem, 2001). Examples include hepatitis B virus X
protein (HBx), which activates Ca2+ signaling through
mitochondria to influence HBV replication (Bouchard et al.,
2001), and strains of rotavirus that encode NSP4, a nonstruc-
tural glycoprotein that increases the cytosolic calcium in
infected cells (Tian et al., 1995). In addition, Kaposi's
sarcoma-associated herpesvirus (KSHV) mitochondrial protein
K7 targets CAML, a cellular Ca2+-modulating protein to
increase cytosolic Ca2+ allowing the completion of lytic
replication (Feng et al., 2002). Coxsackievirus protein 2B
induces the influx of extracellular Ca2+ and releases Ca2+ from
ER stores, modifying plasma membrane permeability to
facilitate virus release (van Kuppeveld et al., 1997). HIV-1
Nef causes atypical IP3R triggering of plasma membrane
calcium influxes, independent of intracellular calcium stores
(Manninen and Saksela, 2002). Furthermore, calcium plays a
critical role in the replication cycles or pathogenesis of other
viral infections including poliovirus, cytomegalovirus, vaccinia,
and measles (Ruiz et al., 2000).
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for the singly and doubly spliced ORF I mRNA in context to an
infectious clone of HTLV-1 is associated with a reduction of
viral infectivity in vivo (Collins et al., 1998) that can be model
when resting T cells are used as targets in vitro (Albrecht et al.,
2000). In addition, nucleotide sequence alleles of p12I including
those that would result in specific residue changes associated
with protein stability (lysine versus arginine at position aa 88) or
truncation mutants have been reported in a minority (<7%) of
HTLV-1-infected subjects with HAM/TSP, ATL, and asympto-
matic patients (Martins et al., 2002; Furukawa et al., 2004;
Iniguez et al., 2006). In this minority subset of infected persons,
it appears that the presence of a lysine residue at position 88 of
the protein is not a specific marker for HAM/TSP (Martins et
al., 2002) and that truncations of p12I (e.g., premature stop
codons leading to p12I variants from 82 to 86 amino acids in
length) do not preclude transmission (Furukawa et al., 2004;
Iniguez et al., 2006). These findings are consistent with our data
using exogenously express truncation mutants of p12I, which
retain the ability to localized to subcellular compartments, and
elicited calcium-mediated NFAT activation of T cells (Ding et
al., 2002; Kim et al., 2003).
p300 forms complexes with other transcription factors at the
HTLV-1 promoter and plays a critical role in the regulation of
HTLV-1 transcription in infected T cells (Lemasson et al.,
2002). HTLV-1 Tax activates the HTLV-1 LTR through its
interaction with p300 (Bex and Gaynor, 1998; Kashanchi et
al., 1998; Jiang et al., 1999) and directly interacts with p300 in
an acetyltransferase/activator complex (Harrod et al., 2000).
We have demonstrated that HTLV-1 p30II binds p300 at the
highly conserved KIX region (Zhang et al., 2001). Intriguingly,
the KIX domain is also the binding site of p300 for HTLV-1
Tax. At lower concentrations, p30II activates HTLV-1 LTR-
mediated transcription and at higher concentrations, p30II
represses LTR-mediated transcription (Zhang et al., 2000). In
addition, p30II was able to disrupt CREB-Tax-p300 complexes
bound to the viral 21-bp TRE repeats (Zhang et al., 2001).
Thus, HTLV-1 p30II and Tax appear to compete with each
other in modulating the transcriptional activity from the LTR,
possibly through competitive binding to p300 (Michael et al.,
submitted for publication). Our data present herein indicate
that p12I blocks the repression LTR-driven transcription by
HTLV-1 p30II. These findings indicate that p12I-mediated
enhancement of p300 expression may not only regulate
cellular gene expression to promote lymphocyte survival, but
may also cooperate with other viral proteins to regulate viral
gene expression.
Overall, our study demonstrates that HTLV-1 p12I enhances
the expression of p300, an important but limiting co-activator of
transcription in T cells. Thus, HTLV-1 p12I alters calcium-
dependent cell signaling to promote lymphocyte survival, a
characteristic of HTLV-1-associated lymphoproliferative dis-
orders. In addition, we demonstrate that p12I has the capacity to
reverse the transcriptional repression of p30II on the HTLV-1
LTR in a p300-dependent manner, demonstrating that HTLV-1
accessory proteins have the capacity to act cooperatively to
modulate viral gene expression.Materials and methods
Cells and plasmids
Jurkat Tcells (clone E6-1, catalog # TIB-152, American Type
Culture Collection) were maintained in RPMI 1640 media
(Invitrogen) supplemented with 15% FBS, 100 μg/ml strepto-
mycin/penicillin, 2 mM L-glutamine, and 10 mM HEPES
(Invitrogen). The pME-18S and pME-p12I plasmids (Mulloy et
al., 1996) were provided by G. Franchini (National Cancer
Institute, National Institutes of Health). The pME-p12I plasmid
expresses the fusion protein of HTLV-1 p12I tagged with the
influenza hemagglutinin (HA1) tag. Generation of p12I trunca-
tion mutants in the pME-18S vector was previously described
(Ding et al., 2001). Mutant p12I15-47KKLL, which was
constructed by inserting an ER targeting (Gomord et al., 1999;
Plemper et al., 2001) KKLL sequence, has been described pre-
viously (Ding et al., 2003). Plasmid p5XGT-TATA-Luc
(P. Quinn, The Pennsylvania State University, Hershey, PA),
contains five tandem Gal4 DNA-binding sequences upstream of
a TATA box, derived from positions −264 to +11 of the
phosphoenolpyruvate carboxykinase (PEPCK) gene in a
luciferase reporter gene plasmid. The pRSV-β-Gal, 12SE1A,
12SE1A-ΔCR1, and 12SE1A-ΔCR2 (T.Kouzarides, University
of Cambridge, Cambridge, UK) have been described previously
(Zhang et al., 2000, 2001). The pTRE-Luc plasmid and pRSV-β-
Gal have been described previously (Zhang et al., 2000, 2001).
pME-p30IIHA plasmid, which was created by cloning the p30II
sequence fromHTLV-1molecular clone, ACHwith downstream
influenza hemagglutinin (HA1) tag, into pME-18S plasmid (G.
Franchini, National Cancer Institute) between 5′ EcoRI and 3′
NotI sites, has been described previously (Michael et al., sub-
mitted for publication). The lentiviral vector system for ex-
pression of HTLV-1p12I has been described (Nair et al., 2005).
Stimulation of Jurkat T cells
To identify the optimal concentration and time frame for
calcium-mediated enhancement of the transcription of p300,
Jurkat T cells were stimulated with 25, 50, 100, and 500 nM
and 1 μM ionomycin. To identify mRNA levels of p300, RT-
PCR was performed between 36 and 48 h post-stimulation,
whereas western blot and luciferase assays were performed at
60 h post-stimulation. The calcium chelator BAPTA-AM
[glycine, N,N-1,2-ethanediylbis(oxy-2,1-phenylene)-bis-N-2-
(acetyloxy) methoxy-2-oxoethyl]-[bis(acetyloxy)methyl ester]
(Molecular Probes) and calcineurin inhibitor cyclosporin A
(Sigma) were added to Jurkat T cells 24 h post-transfection or
post-stimulation with ionomycin for 1 h at 37 °C. Transfected
cells were washed and resuspended in cRPMI, whereas cells
stimulated with ionomycin were resuspended in cRPMI
containing appropriate concentrations of ionomycin.
Semi-quantitative RT-PCR for p300
Total cellular RNA was isolated from Jurkat T lymphocytes
stimulated with ionomycin, using RNAqueous as described by
255A.M. Nair et al. / Virology 353 (2006) 247–257the manufacturer (Ambion). One microgram RNAwas reversed
transcribed to cDNA as described by the manufacturer (Reverse
Transcription system, Promega). cDNA from 100 ng of total
RNAwas then PCR amplified with AmpliTaq DNA polymerase
(Perkin Elmer) using primers specific for p300 and GAPDH.
The PCR primers are as follows: p300: GTAGCCTAAAAGA-
CAATTTTCCTTG (forward), ATGTCAACCATCTGCAC-
CAGTA (reverse); and GAPDH: TGCACCACCAACTGCT-
TAG (forward), GAGGCAGGGATGATGTTC (reverse). PCR
was performed at multiple cycles to maintain the amplification
in a linear range. PCR products were separated by agarose gel
electrophoresis and densitometric analysis was performed using
alpha imager spot densitometry (Alpha Innotech) as described
previously (Albrecht et al., 1998). Densitometric values for
p300 were normalized using the values for GAPDH. Statistical
analysis was performed using Student's t test, P < 0.05. DNA
contamination tested in samples by performing a control with
no reverse transcriptase.
Analysis of p300 promoter
From the National Center for Biological Information
(NCBI) Web-based resource (http://www.ncbi.nlm.nih.gov/),
the mRNA nucleotide sequence for p300 (NM_001429) was
obtained. Preceding from the predicted start site of p300
mRNA, 403 nucleotide sequences were analyzed using
commercially available software (Genomatix: http://www.
genomatix.de/) to analyze and predict transcription factor
binding sites in the promoter region in the p300 gene
(Chromosome 22, contig-NT_01150.09, Homo sapiens
chromosome 22).
Western immunoblot assays
Western immunoblot assays for the detection of p300 were
performed as described previously (Zhang et al., 2000, 2001).
Briefly, cells were lysed in RIPA buffer containing phosphate-
buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate (SDS). Cell lysates were
prepared by centrifugation at 14,000 rpm (Beckman) for 20 min
at 4 °C. Equal amounts of proteins were mixed with Laemmli
buffer (62.5 mM Tris [pH 6.8], 2% SDS, 10% glycerol, 0.2%
bromophenol blue, 100 mM dithiothreitol). After boiling for
5 min, samples were electrophoresed through 5% polyacryla-
mide gels. The fractionated proteins were transferred to
nitrocellulose membranes (Amersham Pharmacia Biotechnol-
ogy) at 100 V for 1 h at 4 °C. Membranes were then blocked in
Tris-buffered saline containing 5% nonfat milk and 0.1% Tween
20. p300 was detected with the rabbit anti-p300 primary
antibody (Santa Cruz Biotechnology, catalog # SC-584),
followed by an anti-rabbit immunoglobulin G (IgG)–horse-
radish peroxidase-conjugated goat antibody (Upstate). GAPDH,
used as a normalization control, was detected using goat
anti-GAPDH primary antibody (Santa Cruz) followed by an
anti-goat immunoglobulin G (IgG)–horseradish peroxidase-
conjugated donkey antibody (Upstate). Blots were deve-
loped using an enhanced chemiluminescence detection system(NEN Life Science). Densitometric analysis of radiograph was
performed using Gel pro analyzer software (Media Cybernatic
Inc.) and normalized to GAPDH. Protein detection was
optimized to test proteins in the linear range of expression by
testing at various protein concentrations and exposure times.
Statistical analysis was performed using Student's t test,
P < 0.05.
Reporter gene assays
Unless otherwise mentioned, all the transfections of Jurkat T
cells were performed using Superfect transfection reagent
according to manufacturer's instructions (Qiagen). Jurkat T
lymphocytes (2 × 106) were transfected with 500 ng of 5xGT-
luc, 100 ng of pM-VP 16,500 ng of pRSV-β-Gal in the presence
or absence of increasing amounts of wild-type or mutant
12sE1A, and stimulated with appropriate amounts of ionomy-
cin. When the effect of HTLV-1 p12I on p300 expression was
tested, either pME-p12IHA or pME-18s were transfected with
the above described plasmids in the absence if ionomycin. To
test the effect of p12I on HTLV-1 p30II-mediated LTR
repression, 0.2 μg of pTRE-Luc reporter plasmid was co-
transfected with 1.2 μg pME-p30IIHA and increasing concen-
trations (0.0, 0.6, 1.2, and 2.4 μg) of pME-p12IHA using
Lipofectamine Plus (Invitrogen). To test if the rescue of p30II-
mediated HTLV-1 LTR repression by p12I is p300 dependent,
1.0 μg E1A expression plasmid was also co-transfected. As an
internal control for transfection efficiency, 0.1 μg of pRSV-β-
Gal (Invitrogen) was used in each transfection. pME-18S was
used as carrier DNA to equalize DNA concentrations for each
transfection.
At 60 h post-transfection, cells were lysed with a
commercial buffer (Promega) at room temperature for
15 min. Twenty microliters of each lysate was used to test
luciferase reporter gene activity using an enhanced luciferase
assay kit according to the manufacturer's protocol (Promega).
Staining with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyra-
noside (X-Gal) (Sigma) and counting β-Gal-expressing cells
were performed to normalize the transfection efficiency. The
final concentration of ionomycin and BAPTA-AM used was
chosen after multiple pilot experiments using different
concentrations of these reagents. BAPTA-AM alone did not
have any significant effect on luciferase expression without
the presence of calcium. Data were expressed as mean of
normalized luciferase activity in arbitrary light units (ALU)
with standard error (SE) from a minimum of triplicate
experiments. Statistical analysis was performed using Stu-
dent's t test, P < 0.05.
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